Irinotecan hydrochloride盐酸伊立替康

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Irinotecan hydrochloride trihydrate

CAS No. : 136572-09-3

MCE 国际站：Irinotecan hydrochloride trihydrate

产品活性：Irinotecan hydrochloride trihydrate ((+)-Irinotecan hydrochloride trihydrate) 是一种拓扑异构酶 I (topoisomerase I) 抑制剂，可用于结肠癌和直肠癌的研究。

研究领域：Cell Cycle/DNA Damage  |  Autophagy

作用靶点：Topoisomerase  |  Autophagy

In Vitro: Irinotecan hydrochloride trihydrate is a topoisomerase I inhibitor. Irinotecan inhibits the growth of LoVo and HT-29 cells, with IC₅₀s of 15.8 ± 5.1 and 5.17 ± 1.4 μM, respectively, and induces similar amounts of cleavable complexes in both in LoVo and HT-29 cells. Irinotecan suppresses the proliferation of human umbilical vein endothelial cells (HUVEC), with an IC₅₀ of 1.3 μM.

In Vivo: Irinotecan (CPT-11, 5 mg/kg) significantly inhibits the growth of tumors by intratumoral injection daily for 5 days, on two consecutive weeks in rats, and such effects also occur via continuous intraperitoneal infusion by osmotic minipump into mice. However, Irinotecan (10 mg/kg) shows no effect on the growth of tumor by i.p. Irinotecan (CPT-11, 100-300 mg/kg, i.p.) apparently suppresses tumor growth of HT-29 xenografts in athymic female mice by day 21. The two groups of Irinotecan (125 mg/kg) plus TSP-1 (10 mg/kg per day) or Irinotecan (150 mg/kg) in combination TSP-1 (20 mg/kg per day) are nearly equally effective and inhibit tumor growth 84% and 89%, respectively, and both are more effective than Irinotecan alone at doses of 250 and 300 mg/kg.

相关产品：Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  FDA-Approved Drug Library Mini  |  Bioactive Compound Library Plus  |  Cell Cycle/DNA Damage Compound Library  |  FDA-Approved Drug Library  |  Anti-Cancer Compound Library  |  CNS-Penetrant Compound Library  |  Autophagy Compound Library  |  Anti-Aging Compound Library  |  Drug Repurposing Compound Library  |  NMPA-Approved Drug Library  |  FDA Approved & Pharmacopeial Drug Library  |  Anti-Lung Cancer Compound Library  |  Drug-Induced Liver Injury (DILI) Compound Library  |  Anti-Pancreatic Cancer Compound Library  |  Children’s Drug Library  |  Chemotherapy Drug Library  |  FDA-Approved Anticancer Drug Library  |  Human Metabolite Library  |  Anti-Prostate Cancer Compound Library  |  Off-patent Drug Library  |  Highly Selective Inhibitors Library  |  Highly Selective Activators Library  |  Cell Death Library  |  Doxorubicin hydrochloride  |  Etoposide  |  Exatecan mesylate  |  SN-38  |  Irinotecan  |  Camptothecin  |  Topotecan hydrochloride  |  Daunorubicin hydrochloride  |  Mitoxantrone  |  Berberine chloride  |  Epirubicin hydrochloride  |  Ciprofloxacin  |  Levofloxacin  |  Betulinic acid  |  EIDD-1931  |  Suramin sodium salt  |  Idarubicin hydrochloride  |  Gepotidacin  |  β-Lapachone  |  Aldoxorubicin  |  Pirarubicin  |  Teniposide  |  Banoxantrone dihydrochloride

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds